A5078109432- Chronic Myeloid Leukemia Treatments
- Eosinophilic Disorders and Syndromes
- Mast cells and histamine
- Chronic Lymphocytic Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Acute Myeloid Leukemia Research
- Asthma and respiratory diseases
- Acute Lymphoblastic Leukemia research
- Lymphoma Diagnosis and Treatment
- Urticaria and Related Conditions
- Allergic Rhinitis and Sensitization
- Click Chemistry and Applications
- melanin and skin pigmentation
- Eosinophilic Esophagitis
- Multiple Myeloma Research and Treatments
- Immunodeficiency and Autoimmune Disorders
- Monoclonal and Polyclonal Antibodies Research
- Food Allergy and Anaphylaxis Research
- Hematological disorders and diagnostics
- Histiocytic Disorders and Treatments
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Lung Cancer Research Studies
- Immune Cell Function and Interaction
- Neutropenia and Cancer Infections
- Blood disorders and treatments
Istituti di Ricovero e Cura a Carattere Scientifico
2009-2019
University of Pavia
2006-2019
Policlinico San Matteo Fondazione
2006-2018
James Cook University Hospital
2013-2018
Ceinge Biotecnologie Avanzate (Italy)
2007
Policlinico S.Orsola-Malpighi
2007
University of Bologna
2007
University of Naples Federico II
2006
Background and Objectives The hypereosinophilic syndrome (HES) may be associated with the fusion of platelet derived growth factor receptor α (PDGFRα) gene FIP1L1 in chromosome 4 coding for a constitutively activated PDGFRα tyrosine kinase. These cases FIP1L1-PDGFRα rearrangement have been reported to very sensitive kinase inhibitor imatinib mesylate.Design Methods A prospective multicenter study idiopathic or primary HES was established 2001 (Study Protocol Registration no. NCT 0027 6929)....
Systemic mastocytosis is a rare heterogeneous myeloproliferative neoplasm characterized by abnormal proliferation and activation of mast cells. We describe large multicentre series 460 adult patients with systemic mastocytosis, diagnosis based on WHO 2008 criteria, in “real‐life” setting ten Italian centers dedicated multidisciplinary programs. included indolent forms ( n = 255) without 165) skin lesions, smouldering 20), aggressive 28), associated other hematological diseases 21) cell...
Abstract Purpose: Most patients with chronic-phase chronic myeloid leukemia (CML) who receive imatinib achieve a complete cytogenetic remission (CCgR) and low levels of BCR-ABL transcripts. CCgR is durable in the majority but relapse occurs subset. Experimental Design: To determine potential quantitative reverse transcription-PCR to predict relapse, we serially monitored residual disease 97 CML an imatinib-induced CCgR. Patients late phase after IFN-α failure were treated (400 mg daily)....
Background Imatinib mesylate is the first line treatment for chronic myeloid leukemia. The advent of imatinib increased survival significantly in patients an advanced phase disease. However, few long-term data on outcome these based large, prospective and controlled trials are available.Design Methods A 2 multicenter trial use 600 mg/daily with accelerated leukemia was sponsored promoted by Italian Cooperative Study Group Chronic Myeloid Leukemia 2001.Results One hundred eleven were...
Summary Background In mastocytosis, the skin is almost invariably involved, and cutaneous symptoms deeply affect patients' quality of life. Methods A retrospective observational analysis patients affected by mastocytosis ( CM ) indolent systemic ISM treated with phototherapy/photochemotherapy PUVA or NB ‐ UVB has been conducted. For each patient, total numbers exposures, cumulative UV dose (J/cm 2 ), serum tryptase profile, pruritus, before after treatment, according to visual analogue scale...
The molecular basis of advanced systemic mastocytosis (SM) is not fully understood and despite novel therapies the prognosis remains dismal. Exome sequencing an index-patient with mast cell leukemia (MCL) uncovered biallelic loss-of-function mutations in SETD2 histone methyltransferase gene. Copy-neutral loss-of-heterozygosity at 3p21.3 (where maps) was subsequently found SM patients prompted us to undertake in-depth analysis copy number, mutation status, transcript expression methylation...
Abstract Background Mastocytoses represent a heterogeneous group of stem cell disorders marked by an abnormal hyperplasia and accumulation mast cells in one or more tissues, including bone marrow, gastrointestinal tract, liver, spleen, lymph nodes skin. Indolent systemic mastocytosis (ISM) is characterized red‐brownish pruriginous maculopapular lesions, marrow infiltration without functional impairment indolent clinical course with good prognosis. In particular, the most common cutaneous...
In a series of 172 patients with non-Hodgkin's lymphoma (NHL) classified according to the Working Formulation (WF) overall incidence bone marrow infiltration (BM+) at diagnosis was 39%: 59% for low-grade (LGML), 30% intermediate-grade (IGML), and 25% high-grade malignant lymphomas (HGML). The features most significantly correlated presence BM+ were low grade histological malignancy, degree splenomegaly high values LDH, while those extent non-focal pattern BM disease, blood involvement...
23 adult patients with refractory or relapsed acute myelogenous leukemia (AML) received salvage chemotherapy mitoxantrone and etoposide. The regimen consisted of mitoxantrone, 10 mg/m2/d by 30-min infusion, etoposide 100 given 12 h apart for 5 consecutive d. Of treated, 13 met the criteria highly disease (6 primary resistant; 4 early relapse during maintenance; 3 to reinduction). had off-therapy more than 6 months after achieving first CR. Overall, 14 (61%) achieved a complete remission...
Interferon α (IFNα) prolongs survival of CML patients achieving CCyR and potentially synergizes with TKIs. We report on the molecular status long term outcome 121 who were treated in Italy between 1986 2000 IFNα based therapy obtained CCyR. After a median follow up 16.5 years, 74 (61%) switched to standard imatinib: 48 (65%) lost IFNα, 36 (75%) are alive CCyR; 26 (35%) imatinib when they still all Forty-seven (39%) never 24 (51%) continued 23 (49%) discontinued respectively, 39/47 (83%) At...